Sukumar Nagendran
2023 - Taysha Gene Therapies
In 2023, Sukumar Nagendran earned a total compensation of $1.2M as President and Head of Research and Development at Taysha Gene Therapies, a 8% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $254,250 |
|---|---|
| Option Awards | $427,526 |
| Salary | $565,000 |
| Other | $1,344 |
| Total | $1,248,120 |
Nagendran received $565K in salary, accounting for 45% of the total pay in 2023.
Nagendran also received $254.3K in non-equity incentive plan, $427.5K in option awards and $1.3K in other compensation.
Rankings
In 2023, Sukumar Nagendran's compensation ranked 977th out of 3,006 executives tracked by ExecPay. In other words, Nagendran earned more than 67.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 977 out of 3,006 | 68th |
Division Manufacturing | 579 out of 1,650 | 65th |
Major group Chemicals And Allied Products | 396 out of 918 | 57th |
Industry group Drugs | 385 out of 881 | 56th |
Industry Biological Products, Except Diagnostic Substances | 117 out of 213 | 45th |
Source: SEC filing on April 18, 2024.
Nagendran's colleagues
We found two more compensation records of executives who worked with Sukumar Nagendran at Taysha Gene Therapies in 2023.